A Phase 3 interventional study of Etelcalcetide and Standard of Care in Secondary Hyperparathyroidism and Chronic Kidney Disease, sponsored by Amgen. Recruiting at 43 sites in 10 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary — 2 open to participants now, 2 under way, 2 of them phase 3. etelcalcetide · Hyperparathyroidism, Secondary.
Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, this one is the 9th largest by planned enrollment, is one of 2 that started in 2019, is one of 9 in phase 3, and was the 15th registered.
188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.
Browse Hyperparathyroidism, Secondary studies →2 of the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary are open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in Belgium, Czechia, France and 9 more countries
Ages 2–17
By country, each count listing its studies:
etelcalcetide: first FDA approval 2017 (PARSABIV), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 56 is close to the median of 62 across 146 interventional studies indexed under Hyperparathyroidism, Secondary.
Median enrollment 72 across the 16 interventional studies. Of the 14 that completed or were terminated, 14 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 2 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 167 (68%) have results posted.
33 studies in Hyperparathyroidism, Secondary by Amgen: 2 open now, 2 under way, 2 of them phase 3. Of 31 finished, 22 (71%) have results posted.
Among the 33 studies in Hyperparathyroidism, Secondary by Amgen, this one is the 21st largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2019, is one of 16 in phase 3, and was the 32nd registered.
Amgen’s Hyperparathyroidism, Secondary studies by the year they started, since 2001.
1 of the studies testing etelcalcetide in Hyperparathyroidism, Secondary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing etelcalcetide in Hyperparathyroidism, Secondary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 33 in Hyperparathyroidism, Secondary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
SHPT is a common and serious co-morbidity that develops relatively early in the course of CKD, worsens with declining kidney function, and is associated with serious complications in children on dialysis. Children on dialysis experience a wide spectrum of bone abnormalities and growth retardation, in addition to increased risk for cardiovascular morbidity and mortality that manifests early in their adulthood. Traditional therapies for SHPT (eg, vitamin D sterols) are widely used in the pediatric dialysis population, and have the potential to aggravate complications of the disease by increasing serum calcium (Ca), serum phosphorus, and serum Ca times serum phosphorus product.
Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus, and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe. Although no previous trials have been conducted in pediatric patients with etelcalcetide (one single dose pharmacokinetic [PK] trial is currently ongoing), Amgen anticipates minimal to moderate risk with a possibility of direct benefit to the pediatric participants (age 28 days to 18 years) in this trial. The burden of complications of SHPT in the pediatric dialysis population and the limitations of current standard therapy, underscore the need for trials of etelcalcetide in these patients to address this unmet medical need and inform the pediatric nephrology community of the potential use of etelcalcetide in children on hemodialysis with critical safety and efficacy data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria Disease Related
Other Medical Conditions
Prior/Concomitant Therapy
Prior/Concurrent Clinical Trial Experience • Currently receiving treatment in another device or drug trial, or less than 30 days or 5 half-lives (whichever is longer) since ending treatment on another investigational device or drug trial(s). Other investigational procedures while participating in this trial are excluded.
Diagnostic Assessments During Screening
Within the 60 days prior to enrollment
Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are randomized in a 5:1 ratio to receive etelcalcetide in addition to standard of care versus standard of care alone.
Drug: Etelcalcetide · Other: Standard of Care
Participants are randomized in a 5:1 ratio to receive etelcalcetide in addition to standard of care versus standard of care alone.
Other: Standard of Care
Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling iPTH, Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
Also known as: Parsabiv
Standard of care, which can include therapy with vitamin D sterols, Ca supplementation, and/or phosphate binders
Percentage of Participants Achieving a ≥ 30% Reduction from Baseline in Mean iPTH During the Efficacy Assessment Period (EAP)
Achievement of at least a 30% reduction from baseline in mean iPTH during the EAP (defined as weeks 20 through 27).
Time frame: Baseline and Weeks 20-27
Percentage Change from Baseline in Mean iPTH During the EAP
Percent Change from Baseline in Mean iPTH During EAP (defined as weeks 20 through 27).
Time frame: Baseline and Weeks 20-27
Maximum Serum Concentration (Cmax) of Etelcalcetide
Cmax will be collected and reported for the etelcalcetide arm only.
Time frame: 10-30 minutes post dose on Day 1 and 10-30 minutes post dose on Weeks 5, 9, 13, 17, and 21
Minimum Serum Concentration (Cmin) of Etelcalcetide
Cmin will be collected and reported for the etelcalcetide arm only.
Time frame: 10-30 minutes post dose on Day 1 and 10-30 minutes post dose on Weeks 5, 9, 13, 17, and 21
Number of Participants who Experienced Adverse Events (AEs)
To characterize the safety of etelcalcetide treatment based on adverse events. Nature, frequency, severity, and relationship to treatment of all adverse events, including those of special interest reported during the trial.
Time frame: Day 1 to 30 days after last dose of etelcalcetide (up to approximately 30 weeks)
Frequency of Hypocalcemia
Occurrence of hypocalcemia at any point in time, assessed by serum chemistry.
Time frame: Up to approximately 30 Weeks
Number of Participants with Corrected Serum Ca Levels at any Time During the Trial
Occurrence of corrected serum Ca levels \<8.0 mg/dL (2.0 mmol/L) for participants 2 to \< 18 years of age and \<8.6 mg/dL (2.15 mmol/L) for participants 28 days to \<2 years of age during the trial.
Time frame: Up to approximately 30 Weeks
Number of Participants with Serum Phosphorous Levels Below Normal by Age Group
Occurrence of serum phosphorous levels below the lower limit of normal by age group.
Time frame: Up to approximately 30 Weeks
Number of Participants with Predialysis iPTH Levels Below Normal by Age Group
Occurrence of predialysis iPTH levels below the lower limit of normal by age group.
Time frame: Up to approximately 30 Weeks
Change from Baseline in Systolic Blood Pressure
To characterize the safety of etelcalcetide treatment based on vital signs.
Time frame: Week -2, Week -1, Day1, and Weeks 4, 8, 12, 16, 20, 24, and 27
Change from Baseline in Diastolic Blood Pressure
To characterize the safety of etelcalcetide treatment based on vital signs.
Time frame: Week -2, Week -1, Day1, and Weeks 4, 8, 12, 16, 20, 24, and 27
Change from Baseline in Heart Rate
To characterize the safety of etelcalcetide treatment based on vital signs.
Time frame: Week -2, Week -1, Day1, and Weeks 4, 8, 12, 16, 20, 24, and 27
Change in Tanner Stage
Changes in tanner stage at scheduled visits.
Time frame: Week -2 and Week 27
Change in Height
Changes in height at scheduled visits.
Time frame: Day 1 and Week 27
Change in Weight
Changes in weight at scheduled visits.
Time frame: Week -2, Day 1, and Week 27
Number of Participants Achieving ≥ 30% Reduction in iPTH from Baseline on two Consecutive Visits
To characterize change in laboratory markers of CKD following etelcalcetide treatment.
Time frame: Up to approximately 30 Weeks
Mean Change from Baseline in Predialysis iPTH from Baseline during the EAP
Mean change from baseline in predialysis iPTH during the EAP (defined as weeks 20 through 27).
Time frame: Baseline and Weeks 20-27
Percentage Change from Baseline in Corrected Total Serum Ca from Baseline During the EAP
Percentage change from baseline in corrected total serum Ca during the EAP (defined as weeks 20 through 27).
Time frame: Baseline and Weeks 20-27
Percentage Change from Baseline in Corrected Total Serum Phosphorous from Baseline During the EAP
Percentage change from baseline in corrected total serum phosphorous during the EAP (defined as weeks 20 through 27).
Time frame: Baseline and Weeks 20-27
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Started Apr 2019 (actual). Primary completion is estimated for Jan 2029, 117 months after the start.
Of 21 phase 3 interventional studies under Hyperparathyroidism, Secondary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 117 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etelcalcetide
Hyperparathyroidism, Secondary →